Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: REVATIO

Summary for Tradename: REVATIO

Suppliers: see list3
patent expirations by year for

Pharmacology for Tradename: REVATIO

Clinical Trials for: REVATIO

A Pivotal Bioequivalence Study Between The Sildenafil Powder For Oral Suspension (10 Mg/Ml) And The Sildenafil 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions
Status: Completed Condition: Pulmonary Arterial Hypertention

Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Versus To Viagra® Oral Tablet.
Status: Completed Condition: Erectile Dysfunction

Does Oral Sildenafil (Viagra) Decrease Mean Pulmonary Artery Pressure After Cardiac Surgery?
Status: Recruiting Condition: Pulmonary Hypertension

Sildenafil in Single Ventricle Patients
Status: Completed Condition: Heart Disease

Effects of Viagra on Heart Function in Patients With Heart Failure
Status: Completed Condition: Heart Failure; Left Ventricular Dysfunction

Effect of Adding Sildenafil to Protocol of Endometrial Preparation in Outcome of Frozen-thawed Embryo Transfer Cycles
Status: Completed Condition: Endometrial Preparation; Frozen Embryo Transfer

Sildenafil for Prevention of Cerebral Vasospasm
Status: Recruiting Condition: Subarachnoid Hemorrhage; Cerebral Vasospasm; Rupture of Intracranial Aneurysm

Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes
Status: Completed Condition: Diabetes Mellitus, Type 2; Endothelial Dysfunction

Sildenafil (Viagra) Treatment of Subacute Ischemic Stroke
Status: Terminated Condition: Ischemic Stroke

Pharmacokinetics of Sildenafil in Premature Infants
Status: Recruiting Condition: Persistent Pulmonary Hypertension of the Newborn

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
sildenafil citrate
FOR SUSPENSION;ORAL203109Aug 30, 2012RXYes<disabled><disabled>
sildenafil citrate
FOR SUSPENSION;ORAL203109Aug 30, 2012RXYes<disabled><disabled>
sildenafil citrate
FOR SUSPENSION;ORAL203109Aug 30, 2012RXYes<disabled><disabled>
sildenafil citrate
SOLUTION;INTRAVENOUS022473Nov 18, 2009RXYes<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology